Vor Biopharma CMO Christopher Slapak to retire effective May 6, 2022

Vor Biopharma Inc.

Dr. Christopher Slapak, Chief Medical Officer, will terminate employment on May 6, 2022 due to retirement.
Severance benefits consistent with the Company's Executive Severance and Change in Control Benefits Plan.
Separation agreement to be filed as an exhibit to Q2 2022 Form 10-Q.
No successor appointed as of the filing date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Slapak

Chief Medical Officer

VOR · Vor Biopharma Inc.

Effective: 2022-05-06
Filed: April 14, 2022, 7:59 PM ET

On April 11, 2022, Vor Biopharma Inc. (the “Company”) and Christopher Slapak, M.D., Chief Medical Officer of the Company, agreed that Dr. Slapak’s employment with the Company will terminate effective May 6, 2022 in connection with Dr. Slapak’s retirement from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Slapak was terminated as Chief Medical Officer at Vor Biopharma Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

On April 11, 2022, Vor Biopharma Inc. (the “Company”) and Christopher Slapak, M.D., Chief Medical Officer of the Company, agreed that Dr. Slapak’s employment with the Company will terminate effective May 6, 2022 in connection with Dr. Slapak’s retirement from the Company.

View on SEC.gov

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-005694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.